Quince Therapeutics' average one-year price target was revised sharply higher to $40.80 per share from $4.08, a 900% increase. The update is analytically positive for the stock and suggests materially improved expectations, though the article does not cite new operational or clinical catalysts. Market impact is likely limited to sentiment around the name rather than the broader sector.
Quince Therapeutics' average one-year price target was revised sharply higher to $40.80 per share from $4.08, a 900% increase. The update is analytically positive for the stock and suggests materially improved expectations, though the article does not cite new operational or clinical catalysts. Market impact is likely limited to sentiment around the name rather than the broader sector.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
moderately positive
Sentiment Score
0.70
Ticker Sentiment
